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ABSTRACT
Background Infantile-onset encephalopathy and
hypertrophic cardiomyopathy caused by mitochondrial
oxidative phosphorylation defects are genetically
heterogeneous with defects involving both the
mitochondrial and nuclear genomes.
Objective To identify the causative genetic defect in two
sisters presenting with lethal infantile encephalopathy,
hypertrophic cardiomyopathy and optic atrophy.
Methods We describe a comprehensive clinical,
biochemical and molecular genetic investigation of two
affected siblings from a consanguineous family. Molecular
genetic analysis was done by a combined approach
involving genome-wide autozygosity mapping and next-
generation exome sequencing. Biochemical analysis was
done by enzymatic analysis and Western blot. Evidence for
mitochondrial DNA (mtDNA) instability was investigated
using long-range and real-time PCR assays. Mitochondrial
cristae morphology was assessed with transmission
electron microscopy.
Results Both affected sisters presented with a similar
cluster of neurodevelopmental deficits marked by failure to
thrive, generalised neuromuscular weakness and optic
atrophy. The disease progression was ultimately fatal with
severe encephalopathy and hypertrophic cardiomyopathy.
Mitochondrial respiratory chain complex activities were
globally decreased in skeletal muscle biopsies. They were
found to be homozygous for a novel c.1601T>G (p.
Leu534Arg) mutation in the OPA1 gene, which resulted in
a marked loss of steady-state levels of the native OPA1
protein. We observed severe mtDNA depletion in DNA
extracted from the patients’ muscle biopsies. Mitochondrial
morphology was consistent with abnormal mitochondrial
membrane fusion.
Conclusions We have established, for the first time,
a causal link between a pathogenic homozygous OPA1
mutation and human disease. The fatal multisystemic
manifestations observed further extend the complex
phenotype associated with pathogenic OPA1 mutations, in
particular the previously unreported association with
hypertrophic cardiomyopathy. Our findings further
emphasise the vital role played by OPA1 in mitochondrial
biogenesis and mtDNA maintenance.
Mitochondrial disorders are genetically and pheno-
typically highly heterogeneous. Due to the limited
coding capacity of the mitochondrial genome, the
majority of structural and accessory proteins
required for the proper assembly and functioning
of the mitochondrial respiratory chain are encoded
by the nuclear genome. Mutations in an increasing
number of these critical nuclear-encoded genes
have been identified over the past decade by next-
generation sequencing. These advances have
allowed the elucidation of the underlying genetic
diagnosis in patients with complex phenotypes and
also broadened the spectrum of clinical manifesta-
tions associated with specific disease-causing genes.
Syndromes characterised by infantile-onset hyper-
trophic cardiomyopathy and encephalopathy are
genetically heterogeneous, but mitochondrial dys-
function with impairment of mitochondrial oxida-
tive phosphorylation has emerged as an important
pathophysiological mechanism. Accordingly, these
specific syndromes may be caused by mutations in
various genes involving both the mitochondrial or
nuclear genomes. Unsurprisingly, a number of
nuclear genes causing isolated or combined mito-
chondrial respiratory chain defects have been iden-
tified in patients with infantile hypertrophic
cardiomyopathy and variable forms of encephalop-
athy, of which recent examples include NDUFV2,
COX6B1, and SCO2.1–3
Heterozygous OPA1 mutations cause autosomal
dominant optic atrophy (DOA), which is the most
common form of inherited mitochondrial blindness
with a minimum prevalence of 1 in 25 000 in the
general population.4 Here, we report on two sib-
lings from a consanguineous family who presented
with a fatal, infantile-onset, global encephalopathy
and progressive hypertrophic cardiomyopathy due
to a novel homozygous mutation in the OPA1
gene. Homozygous OPA1 mutations have not been
reported previously and the unexpected association
with cardiac involvement further broadens the
genotypic and phenotypic spectrum associated with
syndromic DOA.
The subjects of this study are two sisters of Arab
Muslim origin and their parents are entirely
healthy first-degree cousins with no visual or
neurological complaints. Patient I-1 was born pre-
maturely at 35 weeks gestation and failure to thrive
was a problem since birth. At 2 months of age, she
was also noted to have truncal hypotonia that was
replaced by multiple episodes of hypertonia and
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opisthotonic posturing. Furthermore, she had a weak cry and
abnormal eye pursuits. An initial echocardiography and ophthal-
mological examinations performed at that time were unremark-
able. Metabolic investigations revealed elevated serum alanine
and lactate levels, but a normal cerebrospinal fluid (CSF) lactate
concentration. Disease progression was marked by a persisting
failure to thrive with severe neurodevelopmental delay, but
brain MRI was normal. The patient subsequently developed a
progressive, non-obstructive, generalised hypertrophic cardio-
myopathy, in the absence of overt heart failure. The patient died
at 10 months of age following an apnoeic episode.
Patient I-2 was born at term following a caesarean section due
to breech presentation. Two days later, she developed general-
ised hypertonia and opisthotonic posturing, and feeding was
inadequate due to poor suckling. Initial echocardiography
showed mild thickening of the left ventricular myocardium.
Serum and CSF lactate concentrations were both elevated. Brain
MRI performed at 1.5 months of age was normal and no abnor-
mal lactate peaks were detected on functional spectroscopic
imaging. Due to gastro-oesophageal reflux and persisting failure
to thrive, a gastrostomy tube and Nissen funduplication proce-
dures were performed at 3 months of age. The disease course
was further complicated by progressive, hypertrophic, non-
obstructive cardiomyopathy, profound neurodevelopmental
retardation, hypotonia with significant muscle wasting and sen-
sorineural deafness. There was no nystagmus, ptosis or limita-
tion of eye movements. Ophthalmological examination at
6 months of age revealed mild pallor of both optic nerves.
Visual electrophysiology revealed severely attenuated visual
evoked potentials, consistent with primary retinal ganglion cell
pathology, and the electroretinogram responses were signifi-
cantly reduced, indicative of more global retinal degeneration.
The patient died at 11 months of age following an apnoeic
episode while sleeping.
A muscle biopsy was performed at 8 months of age (patient
I-1) and at 1 month of age (patient I-2). Routine mitochondrial
immunohistochemical staining was apparently normal with no
cytochrome c oxidase-deficient muscle fibres. Enzymatic activ-
ities of the five respiratory chain complexes and citrate synthase
(CS) activity, a mitochondrial matrix enzyme marker, were
determined in isolated muscle mitochondria by spectrophoto-
metric assays. This analysis revealed global decrease in all the
respiratory chain complexes when normalised to CS activity in
both patients, with complexes I and IV being the most affected
(table 1) and complex II relatively preserved.
Molecular genetic investigations for both sisters were initiated
after obtaining the relevant written informed consents and local
ethical review board approval. Because of parental consanguinity,
genome-wide homozygosity mapping for both affected sisters was
undertaken using Affymetrix Gene-Chip Human Mapping 50 K
Xba Array and Gene-Chip Human Mapping 250 K NspI Array.
We specifically looked for genes with proven or suspected mito-
chondrial function in light of the generalised oxidative phosphor-
ylation defects detected in both siblings. We identified four large
homozygous chromosomal stretches shared by both siblings (see
online supplementary table S1), which harboured >150 genes, of
which nine had putative mitochondrial involvement. Whole
exome sequencing (HiSeq 2000, mean depth coverage of X 65.9;
see online supplementary methods) and bioinformatic filtering
highlighted a homozygous c.1601T>G variant in the OPA1 gene,
predicting the substitution of a highly evolutionary conserved
leucine at position 534 with arginine (p.Leu534Arg, OPA1
NM_015560.2; see online supplementary figure S1) as the only
mitochondrial-targeted gene that could be functionally relevant.
This previously unreported OPA1 variant affects the GTPase cata-
lytic domain (http://mitodyn.org/home.php?select_db=OPA1,
accessed 22 June 2015) and it was predicted to be disease causing
by Mutation Taster biotool (probability score 0.999, range 0–1.0)
and SIFT (Sorting Intolerant from Tolerant, probability score 1.0,
range, 0–1.0) prediction softwares. Both parents were heterozy-
gous for thisOPA1 variant. They did not report any visual difficul-
ties and a comprehensive neuro-ophthalmological evaluation was
normal. Their optic discs did not look pale on dilated fundus
examination and optical coherence tomography (OCT) imaging
did not show any subclinical thinning of the retinal nerve fibre
layer. The parents have two clinically unaffected sons who were 14
and 11 years old when last reviewed in clinic. The older son is het-
erozygous for the c.1601T>G OPA1 variant, whereas the other
son only carries the wild-type OPA1 allele. This novel OPA1
variant was not detected in a cohort of 120 control subjects of
similar ethnic origin and it was not present in a database including
63 000 exome sequences (Exome Aggregation Consortium; http://
exac.broadinstitute.org, accessed 22 June 2015).
In order to further assess the pathogenicity of this
c.1601T>G OPA1 variant, western blot analysis was performed
on homogenate muscle tissue from patient I–1 using standard
monoclonal antibodies that bind to the C-terminus region of
the OPA1 protein. There was a significant reduction in
steady-state OPA1 protein level in patient I–1 compared with
age-matched controls (figure 1A,B). This observation was con-
sistent with the reduced OPA1 protein levels observed in
another patient (NO-1) with a complicated syndromic DOA
phenotype characterised by optic atrophy and marked general-
ised neurodegenerative features, who has been confirmed to
harbour compound heterozygous OPA1 missense mutations in
exon 5b (c.768C>G, p.Ser256Arg) and exon 8 (c.854A>G, p.
Gln285Arg; figure 1C). To further investigate how a homozy-
gous missense OPA1 mutation could result in markedly reduced
OPA1 protein level, in silico protein modelling was carried out.
The c.1601T>G OPA1 variant replaces a highly hydrophobic
and evolutionary conserved leucine residue with an arginine
residue. Our modelling work suggests that this amino acid sub-
stitution, in the close vicinity of the protein’s critical GTPase
domain, could destabilise the protein, accounting for the signifi-
cantly reduced OPA1 protein level observed on western blot
analysis (see online supplementary figure S2).
Long-range PCR performed on homogenate DNA extracted
from the muscle biopsy specimens of the two affected sisters did
not reveal any multiple mitochondrial DNA (mtDNA) deletions
(see online supplementary figure S3). However, there was evi-
dence of significant mtDNA depletion with a 78% decrease for
patient I-1 and a 78% decrease for patient I-2 compared with
Table 1 Enzymatic activities of mitochondrial respiratory chain
complexes
Assay Patient I-1 Patient I-2 Controls±SD (n=50)
Complex I 0.047 (24%) 0.050 (25%) 0.199±0.043
Complex I+III 0.087 (40%) n.d. 0.217±0.599
Complex II 0.099 (64%) 0.091 (59%) 0.154±0.024
Complex II+III 0.100 (65%) 0.053 (34%) 0.153±0.039
Complex III 0.934 (46%) n.d. 2.01±0.40
Complex IV 0.270 (21%) 0.230 (22%) 1.03±0.24
Complex V 0.151 (44%) n.d. 0.34±0.096
*mU/U citrate synthase (% of control).
n.d. not determined.
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control values (figure 1D). Transmission electron microscopy
(TEM) assay of muscle biopsy from patient I-2 disclosed large
mitochondria with incomplete fusion of the inner mitochondrial
membrane (see online supplementary figure S4).
OPA1 encodes for a large multimeric dynamin-like GTPase
protein, which localises to the inner mitochondrial membrane
where it plays a crucial role in mediating mitochondrial fusion.4
In addition, OPA1 is essential for the assembly and stability of
the mitochondrial respiratory chain supercomplexes,5 mitochon-
drial cristae organisation,6 the sequestration of pro-apoptotic
cytochrome c molecules within these tight junctions and,
importantly, mtDNA maintenance.7 Heterozygous OPA1 muta-
tions account for the majority of cases of non-syndromic DOA,
which classically presents in early childhood with progressive
visual loss. Although optic atrophy is the defining feature of
DOA, non-penetrance has been reported in 10%–20% of OPA1
mutation carriers.4 Furthermore, several papers and recent
reports highlighted the fact that a significant proportion of
OPA1 mutation carriers, up to 20% in a large case series, can
develop a more severe syndromic form of the disease (termed
DOA plus) where the visual loss is compounded by a cluster of
neurological deficits that include chronic progressive external
ophthalmoplegia, sensorineural hearing loss, ataxia, myopathy
and peripheral neuropathy.8 Interestingly, the extraocular mani-
festations of pathogenic OPA1 mutations can sometimes develop
in the absence of overt optic atrophy and visual failure.9 10 As
expected, bi-allelic OPA1 mutations result in a more severe
phenotype characterised by an earlier age of onset and with a
more aggressive neurological course—referred to by some inves-
tigators as Behr syndrome.10–12 More recently, a deep intronic
OPA1 mutation was shown to behave as an intralocus modifier
that results in DOA plus phenotypes when it occurs in conjunc-
tion with an exonic OPA1 missense variant (c.1146A>G, p.-
Ile382Met; NM_015560.2)—the latter being insufficient to
cause disease on its own.13 When present in the heterozygous
state, the c.1601T>G OPA1 variant in our family apparently
does not result in clinical or subclinical disease. Taken together,
these observation further add to the complexity of genotype–
phenotype correlations and it demonstrates the spectrum of
OPA1 mutations from the classical dominant mutations (which
accounts for the majority of cases), to compound heterozygous
mutations causing more severe syndromes (including Behr syn-
drome), and our current report with a homozygous mutation.
Our case report provides a number of new insights into the
molecular and phenotypic manifestations of pathogenic OPA1
mutations. First, the two affected siblings harboured a novel
homozygous OPA1 variant, which have not been reported previ-
ously in association with human disease. These two patients
developed a rapidly progressive lethal phenotype beginning in
early infancy and characterised by marked multisystemic
involvement due to generalised mitochondrial respiratory chain
dysfunction. This ultimately fatal clinical presentation is
Figure 1 (A) Densitometric analysis of OPA1 in muscle tissue from patient I-1. The level of the OPA1 protein was normalised against GAPDH. Four
different control muscle samples were used. Error bars represent SE of the mean. An unpaired Student’s t test was used in statistical comparison
between patient and controls (p=0.0144). (B) Western blot illustrating OPA1 protein levels in muscle controls and muscle tissue of patient I-1.
(C) Densitometric analysis of OPA1 in fibroblasts from patient NO-1 who carries compound heterozygous, c.768C>G (p.Ser256Arg in exon 5b) and
c.854A>G (p.Gln285Arg in exon 8).8 The level of OPA1 protein was normalised against GAPDH. Four different control muscle samples were used.
An unpaired Student’s t test was used in statistical comparison between patient and controls (p=0.0039). (D) MtDNA copy number in skeletal
muscle from the two affected sisters compared with controls. The analysis was performed using a SYBR Green real-time PCR assay with the mtDNA
gene MTND1 corrected against the nuclear gene B2M to calculate mtDNA copy number. Error bars represent SE of the mean. Statistical analysis
performed with Student’s unpaired t test (p<0.0001). *Level of statistical significance.
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consistent with the rather striking observations made in three
Opa1 mouse models. Homozygous mutant mice died in utero
during embryogenesis due to severe abrogation of Opa1 protein
levels, confirming a critical role for this pro-fusion mediator in
early life and development.14–16 In silico modelling indicates
that the c.1601T>G OPA1 missense mutation affects the integ-
rity of the protein structure in the vicinity of the catalytic
GTPase domain, providing a plausible explanation for the sig-
nificant reduction in OPA1 level confirmed by western blot ana-
lysis. OPA1 also forms oligomeric complexes in vivo and the
lack of any wild-type protein due to the homozygous mutations
could further exacerbate protein stability due to impaired
oligomerisation.
Carriers harbouring missense OPA1 mutations affecting the
catalytic GTPase region have a significantly increased risk of
developing the more severe DOA plus phenotype,8 9 which is
again consistent with the rapidly fatal clinical progression
observed for the two affected sisters. Second, hypertrophic car-
diomyopathy has not been reported previously to be associated
with human OPA1 mutations. Interestingly, histopathological
evidence of cardiomyopathy was apparent in a heterozygous
mutant Opa1 mouse model as early as at 5 months of age16 and
the affected cardiac tissues exhibited a combined complex I and
IV respiratory chain defect with reduced ATP production.17
Importantly, previous reports have noted cardiac manifestations
in a number of patients with DOA plus including symptomatic
tachycardia,18 early-onset myocardial infarction19 and sinus
bradycardia.20 These potentially life-threatening associations are
important and further investigations of a larger cohort of
patients with DOA will clarify whether this patient group is at
risk of clinical or subclinical cardiac involvement, and if so, the
need for prophylactic screening and intervention in at-risk
mutation carriers.
Although the precise disease mechanisms by which OPA1
mutations lead to human disease is still under intense investiga-
tion, a growing body of evidence points towards a synergy
between disturbed mitochondrial dynamics, mtDNA instability
and impaired mitochondrial oxidative phosphorylation, which
eventually precipitates an irreversible molecular cascade towards
cell death. Several studies have demonstrated reduced activities
of various mitochondrial respiratory chain complexes, in par-
ticular complex I and complex IV, in muscle biopsies and fibro-
blasts obtained from patients with DOA and confirmed OPA1
mutations.8 21 22 In keeping with these findings, muscle biopsies
from both affected sisters showed a marked global deficiency in
mitochondrial respiratory chain activity, which was relatively
more pronounced for complexes I and IV. It is therefore bio-
logically plausible that such a severe impairment in mitochon-
drial oxidative phosphorylation would have a catastrophic
consequence for tissues with a high basal level of energy con-
sumption such as skeletal muscle, cardiac muscle and the central
nervous system, in addition to the retina.
In addition to the generalised cellular energy shortage, OPA1
is now well established as a regulatory factor involved in
mtDNA maintenance and genome stability. Previous studies
have clearly shown that mtDNA deletions can accumulate to
high levels in postmitotic tissues of affected OPA1 mutation car-
riers.9 22 MtDNA deletions were not detected in the two
affected sisters, which is not surprising given their very young
age and the need for clonal expansion of somatic mtDNA
abnormalities to proceed over several decades before they
become detectable using routine PCR-based detection techni-
ques. However, mtDNA depletion was clearly demonstrated in
both patients—a striking finding that has not been reported
before with pathogenic OPA1 mutations. This observation is
mechanistically important and support a number of recent
studies linking OPA1 and also its sister protein mitofusin 2
(MFN2), with the complex process of mtDNA replication.
OPA1 is thought to physically anchor nucleoids to the inner
mitochondrial membrane via the peptide segment encoded by
exon 4b, and using an elegant series of mouse models, marked
mtDNA depletion was observed in the context OPA1 null
cells.7 23 MFN2 is a major pro-fusion located within the outer
mitochondrial membrane and it works in tandem with OPA1 to
control the sequential steps that eventually lead to mitochon-
drial fusion. Supporting evidence for abnormal inner mitochon-
drial membrane fusion was provided by TEM of patient’s I-2
muscle biopsy. As for OPA1 mutations, MFN2 mutations pre-
dominantly cause the accumulation of multiple mtDNA dele-
tions, but a recent case report indicates that mtDNA depletion
can occur as well.24
It is now abundantly clear that the deleterious consequences
of pathogenic OPA1 mutations are not limited to the optic
nerve. We have further extended the mutational and phenotypic
spectrum of OPA1 disease to include lethal infantile mitochon-
drial encephalomyopathy and hypertrophic cardiomyopathy sec-
ondary to a novel homozygous missense mutation that targets
the key functional GTPase domain. Our case report also further
reinforces the power of next-generation exome sequencing in
elucidating the genetic aetiology of complex disease phenotypes
when combined with rigorous phenotyping and a clear a priori
list of candidate genes, in this particular family, OPA1 given the
clear link with optic atrophy.
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